Biohaven Pharmaceuticals (United States)

Recent papers from Biohaven Pharmaceuticals (United States)

1. Automated Magnetic Resonance Volumetry to Measure Multiple System Atrophy Disease Progression in Clinical TrialsMovement Disorders · 2026
2. Physiologically Based Pharmacokinetic Modeling to Assess Transporter‐Mediated Drug–Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal SprayClinical Pharmacology & Therapeutics · 2026
3. Alzheimer's disease heterogeneity and co‐pathologies: Defining novel targets, biomarkers, modalities, and research methodologiesAlzheimer s & Dementia Translational Research & Clinical Interventions · 2026
4. Exploring Expectation Bias in Parkinson’s Disease Clinical Trials by Comparing Placebo Arm Progression on MDS-UPDRS to a Natural History Dataset (P9-16.010)Neurology · 2026
5. Time to Progression to Wheelchair Comparing Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia (SCA) (S26.009)Neurology · 2026
6. A Novel Mechanism for the Treatment of Autoimmune Neurologic Diseases: Robust, Rapid, and Tunable Removal of IgG with the MoDE™ Degrader BHV-1300 (P5-2.004)Neurology · 2026
7. Compassionate Use of Kv7.2/7.3 Potassium Channel Activator Opakalim (BHV-7000) in a Child with KCNQ2 Developmental and Epileptic Encephalopathy (P10-11.002)Neurology · 2026
8. Opakalim (BHV-7000) Potentiates the Activity of Kv7.2/7.3 Channels Containing a Single Copy of the Kv7.2 DEE-Causing Mutation, G281E (P3-10.009)Neurology · 2026
9. Transmetallation by Halogen-Cyanide Metathesis in Water: Application to Cyanide Ion-Free Palladium Catalyzed CyanationACS Catalysis · 2026
10. Impact of missing patient report outcomes in clinical trials for ulcerative colitis: Should we always assume treatment failure?2026
11. TRPM3 mediates spontaneous pain and mechanical allodynia in a mouse model of chronic orofacial neuropathyCell Reports Medicine · 2026
12. Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)Neurology and Therapy · 2026
13. Patient outcomes in KCNQ2 developmental and epileptic encephalopathyDevelopmental Medicine & Child Neurology · 2026
14. In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplantBlood · 2025
15. Flash Communication: Cobalt-Catalyzed Asymmetric Hydrogenation of a Fluorinated Cyclobutenoic Acid DerivativeOrganometallics · 2025
16. A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraineHeadache The Journal of Head and Face Pain · 2025
17. Development of composite scales for assessing disease progression and treatment effects among patients with Parkinson's disease in a clinical trial settingParkinsonism & Related Disorders · 2025
18. Flash Communication: Cobalt-Catalyzed Asymmetric Hydrogenation of a Fluorinated Cyclobutenoic Acid Derivative2025
19. The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open‐label, single‐dose, parallel‐group studyHeadache The Journal of Head and Face Pain · 2025
20. Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trialsHeadache The Journal of Head and Face Pain · 2025